Arterium

arterium.ua

Arterium
The Arterium Corporation operates in the industry which takes care of the most important values – human health and life.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

QUALIGEN THERAPEUTICS ACQUIRES MAJORITY STAKE IN INFECTIOUS DISEASE DIAGNOSTICS TECHNOLOGY COMPANY NANOSYNEX

Qualigen Therapeutics, Inc. | June 03, 2022

news image

Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...

Read More

JUBILANT RADIOPHARMA AND SOFIE BIOSCIENCES INK STRATEGIC COLLABORATION AGREEMENT TO FURTHER ADVANCE THE FIELD OF MOLECULAR IMAGING & THERAPEUTICS

SOFIE Biosciences, Inc. | November 05, 2020

news image

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to contin...

Read More

Pharmacy Market

HARBOUR BIOMED ANNOUNCES IND APPROVAL FOR NEXT-GEN ANTI-TSLP FULLY HUMAN MONOCLONAL ANTIBODY

Harbour BioMed | February 22, 2022

news image

Harbour BioMed announced that China National Medical Products Administration had approved its investigational new drug (IND) application for HBM9378 a next-gen fully human antibody targeting thymic stromal lymphopoietin for the treatment of moderate-to-severe asthma. HBM9378/SKB378 is a co-development project conducted by HBM and Kelun-Biotech, who together equally share the global rights in respect of HBM9378. The IND approval of HBM9378 is an achievement of the strategic collabo...

Read More

Pharma Tech

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

news image

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More
news image

Business Insights

QUALIGEN THERAPEUTICS ACQUIRES MAJORITY STAKE IN INFECTIOUS DISEASE DIAGNOSTICS TECHNOLOGY COMPANY NANOSYNEX

Qualigen Therapeutics, Inc. | June 03, 2022

Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...

Read More
news image

JUBILANT RADIOPHARMA AND SOFIE BIOSCIENCES INK STRATEGIC COLLABORATION AGREEMENT TO FURTHER ADVANCE THE FIELD OF MOLECULAR IMAGING & THERAPEUTICS

SOFIE Biosciences, Inc. | November 05, 2020

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to contin...

Read More
news image

Pharmacy Market

HARBOUR BIOMED ANNOUNCES IND APPROVAL FOR NEXT-GEN ANTI-TSLP FULLY HUMAN MONOCLONAL ANTIBODY

Harbour BioMed | February 22, 2022

Harbour BioMed announced that China National Medical Products Administration had approved its investigational new drug (IND) application for HBM9378 a next-gen fully human antibody targeting thymic stromal lymphopoietin for the treatment of moderate-to-severe asthma. HBM9378/SKB378 is a co-development project conducted by HBM and Kelun-Biotech, who together equally share the global rights in respect of HBM9378. The IND approval of HBM9378 is an achievement of the strategic collabo...

Read More
news image

Pharma Tech

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us